Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series

被引：0
|
作者：
Shimamoto, Takayuki [1 ]
Morimoto, Yoshie [1 ]
Nitta, Naohiro [1 ]
Yoshida, Rie [1 ]
Tani, Nozomi [1 ]
机构：
[1] Kyoto Kuramaguchi Med Ctr, Dept Pulm Med, Kyoto, Japan
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2024年 / 16卷 / 01期
关键词：
safety; case series; age; malignant pleural mesothelioma; nivolumab plus ipilimumab; CELL LUNG-CANCER; ELDERLY-PATIENTS;
D O I：
10.7759/cureus.52714
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nivolumab plus ipilimumab as the first -line treatment results in superior survival outcomes in patients with malignant pleural mesothelioma (MPM). However, its safety in old (>= 80 years) patients with MPM has not been elucidated yet. Three male patients with MPM, aged 80-90 years, were treated with nivolumab plus ipilimumab as the first -line treatment in our hospital. All of them discontinued the treatment due to adverse events. The overall survival from treatment initiation was 2.5, 3.5, and 4.0 months, respectively. Nivolumab plus ipilimumab should be used cautiously in very old patients with MPM.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
    Laune, Quentin
    Brosseau, Solenn
    BULLETIN DU CANCER, 2022, 109 (01) : 4 - 6
  • [2] First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
    Baas, P.
    Scherpereel, A.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Jahan, T.
    Antonia, S.
    Oulkhouir, Y.
    Bautista, Y.
    Cornelissen, R.
    Greillier, L.
    Grossi, F.
    Kowalski, D. M.
    Rodriguez-Cid, J.
    Aanur, P.
    Baudelet, C.
    Zalcman, G.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E42 - E42
  • [3] Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
    Ye, Zhuo-miao
    Tang, Zi-Qing
    Xu, Zhe
    Zhou, Qin
    Li, Huan
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [4] First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience
    Qaisar, Aitzaz
    White, Mark
    Steele, Nicola
    LUNG CANCER, 2024, 190
  • [5] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA (UMPM) IN THE NETHERLANDS
    Daumont, M. J.
    Torkilseng, E.
    Pompen, M.
    Stevanovic, J.
    Stawowczyk, E.
    VALUE IN HEALTH, 2022, 25 (12) : S113 - S113
  • [6] Real-world Study on Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)
    Aguirre, E. D.
    Enrico, D. H.
    Tissera, N. S.
    Tsou, F.
    Pupareli, C.
    Peralta, D.
    Waisberg, F.
    Rodriguez, A.
    Kaen, D.
    Recondo, G.
    Ramos, M.
    Bluthgen, V.
    Castagneris, N.
    Perfetti, A.
    Levit, P.
    Chacon, M.
    Corrales, L.
    Arrieta, O.
    Cardona, A. F.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S382 - S382
  • [7] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
    Yang, Liu
    Cao, Xueqiong
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [8] First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    Peters, S.
    Scherpereel, A.
    Cornelissen, R.
    Oulkhouir, Y.
    Greillier, L.
    Kaplan, M. A.
    Talbot, T.
    Monnet, I
    Hiret, S.
    Baas, P.
    Nowak, A. K.
    Fujimoto, N.
    Tsao, A. S.
    Mansfield, A. S.
    Popat, S.
    Zhang, X.
    Hu, N.
    Balli, D.
    Spires, T.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 488 - 499
  • [9] Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 30 - 33
  • [10] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
    Scherpereel, Arnaud
    Antonia, Scott
    Bautista, Yolanda
    Grossi, Francesco
    Kowalski, Dariusz
    Zalcman, Gerard
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Sun, Xiaowu
    Lawrance, Rachael
    Zhang, Xiaoqing
    Daumont, Melinda J.
    Bennett, Bryan
    McKenna, Mike
    Baas, Paul
    LUNG CANCER, 2022, 167 : 8 - 16
12345